Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Brentuximab - ODMS; Carboplatin, Etoposide, Ifosfamide - N/A

Citation

Brentuximab vedotin and ICE Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6525/528_v2_B_ICE.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD30 +, HER2-negative Hodgkin Lymphoma Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide